Pharmaceutical Raw Materials Powder Pregabalin/Lyrica CAS 148553-50-8
description
| Product Name: pregabalin | wj1@gzwjsw.com whatsapp +8615512123605 signal +66980528100 |
| Synonyms: | 3(S)-(AMINOMETHYL)-5-METHYLHEXANOIC ACID;(3S)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID;PREGABALIN;Pregablin;3-(Aminomethyl)-5-methyl-hexanoic acid;PREDNISOLONESODIUMPHOSPHATE;(R)-Pregabalin;(S)-Pregabalin |
| CAS: | 148553-50-8 |
| MF: | C8H17NO2 |
| MW: | 159.23 |
| EINECS: | 604-639-1 |
| Mol File: | 148553-50-8.mol |
Product Description
Nervous System API with Pain Relieve Pregabalin CAS 148553-50-8
Pregabalin Quick detail:
| Name | Pregabalin |
| other name | LYRICA |
| Pregabalin Cas No. | 148553-50-8 |
| Pregabalin Molecular formula | C8H17NO2 |
| Pregabalin Molecular weight | 159.23 |
| Pregabalin Purity | 99% |
| Pregabalin Grade | Pharmaceutical grade |
| Pregabalin Appearance | White Crystal Powder |
| Standard | USP standard |
| Package | 25kg/drum |
| Usage | New antiepileptic drugs. Used in the treatment of peripheral neuropathy, or partial seizures |
| 28578-16-7 | PMK ethyl glycidate | High temperature yellow oily/low temperature yellow solid |
| 28578-16-7 | PMK ethyl glycidate | White powder |
| 28578-16-7 | PMK ethyl glycidate | Yellow powder |
| 2079878-75-2 | 2-(2-Chlorophenyl)-5-nitrocyclohexanone | Alternative 2f, white crystal particles |
| 20320-59-6 | Diethyl(phenylacetyl)malonate BMK | Yellow liquid |
| 288573-56-8 | 1-BOC-4-(4-FLUORO-PHENYLAMINO)-PIPERIDINEKS-0037 | White crystalline powder |
| 91393-49-6 | 2-(2-chlorophenyl)cyclohexanone | White puffed powder |
| 10250-27-8 | 2-Benzylamino-2-methyl-1-propanol | White/light yellow powder powder |
| 79099-07-3 | N-(tert-Butoxycarbonyl)-4-piperidone | White or light yellow powder |
| 102-97-6 | N-Isopropylbenzylamine | White crystal |
| 5413-05-8 | Ethyl 2-phenylacetoacetate | White puffed powder |
| 1451-82-7 | 2-Bromo-4'-methylpropiophenone | White puffed powder |
| 593-51-1 | Methylamine hydrochlorideMEDA | White crystal |
| 613-93-4 | N-METHYLBENZAMIDE | White puffed powder |
| 119276-01-6 | Protonitazene (hydrochloride) | Brown block |
| Substitution (etiazepine ) | ||
| 71368-80-4 | Bromazolam | Light pink powder |
| 49851-31-2 | 2-Bromo-1-Phenyl-Pentan-1-One | Yellow liquid |
| 139755-83-2 | Sildenafil | White flash crystalline powder |
| 52190-28-0 | 1-(benzo[d][1,3]dioxol-5-yl)-2-bromopropan-1-one | Brown block |
| 5449-12-7 | 2-methyl-3-phenyl-oxirane-2-carboxylic acid | White or light yellow powder |
| 40064-34-4 | 4,4-Piperidinediol hydrochloride | Off-white or light yellow powder |
| 19099-93-5 | 1-Cbz-4-Piperidone | White powder |
| 877-37-2 | 2-bromo-4-chloropropiophenone | White powder |
| 1451-83-8 | 2-Bromo-1-Phenyl-1-Butanone | White powder |
| 236117-38-7 | 2-iodo-1-p-tolylpropan-1-one | Yellow powder |
| 5337-93-9 | 4-Methylpropiophenone | Yellow liquid |
| 103-81-1 | 2-Phenylacetamide | White powder, soft |
| 123-39-7 | N-methylformamide | Colorless transparent liquid |
| 124878-55-3 | 2-iodo-1-phenyl-pentane-1-one | Yellow liquid |
| 14176-50-2 | Tiletamine Hydrochloride | White crystalline powder |
| 443998-65-0 | 1-BOC-4-(4-BROMO-PHENYLAMINO)-PIPERIDINE | White powder |
| 28281-49-4 | 3,4-(METHYLENEDIOXY)PROPIOPHENONE | White powder |
Medical uses:
Seizures
Pregabalin is useful when added to other treatments, when those other treatments are not controling partial epilepsy. Its use alone is less effective than some other seizure medications. It is unclear how it compares to gabapentin for this use.
Neuropathic pain
The European Federation of Neurological Societies recommends pregabalin as a first line agent for the treatment of pain associated with diabetic neuropathy, post-herpetic neuralgia, and central neuropathic pain. A minority obtain substantial benefit, and a larger number obtain moderate benefit. Other first line agents, including gabapentinand tricyclic antidepressants, are given equal weight as first line agents, and unlike pregabalin, are available as less expensive generics.
Pregabalin is not recommended for certain other types of neuropathic pain such as pain that of trigeminal neuralgia or HIV infection and its use in cancer-associated neuropathic pain is controversial.There is no evidence for its use in the prevention of migraines and gabapentin has been found not to be useful. It has been examined for the prevention of post-surgical chronic pain, but its utility for this purpose is controversial.
Anxiety disorders
Therapeutic effects of pregabalin appear after 1 week of use and is similar in effectiveness to venlafaxine, but pregabalin has demonstrated superiority by producing more consistent therapeutic effects for psychic and somatic anxiety symptoms.Long-term trials have shown continued effectiveness without the development of tolerance, and, in addition, , it has a beneficial effect on sleep and sleep architecture, characterized by the enhancement of slow-wave sleep. and produces less severe cognitive and psychomotor impairment;
Seizures
Pregabalin is useful when added to other treatments, when those other treatments are not controling partial epilepsy. Its use alone is less effective than some other seizure medications. It is unclear how it compares to gabapentin for this use.
Neuropathic pain
The European Federation of Neurological Societies recommends pregabalin as a first line agent for the treatment of pain associated with diabetic neuropathy, post-herpetic neuralgia, and central neuropathic pain. A minority obtain substantial benefit, and a larger number obtain moderate benefit. Other first line agents, including gabapentinand tricyclic antidepressants, are given equal weight as first line agents, and unlike pregabalin, are available as less expensive generics.
Pregabalin is not recommended for certain other types of neuropathic pain such as pain that of trigeminal neuralgia or HIV infection and its use in cancer-associated neuropathic pain is controversial.There is no evidence for its use in the prevention of migraines and gabapentin has been found not to be useful. It has been examined for the prevention of post-surgical chronic pain, but its utility for this purpose is controversial.
Anxiety disorders
Therapeutic effects of pregabalin appear after 1 week of use and is similar in effectiveness to venlafaxine, but pregabalin has demonstrated superiority by producing more consistent therapeutic effects for psychic and somatic anxiety symptoms.Long-term trials have shown continued effectiveness without the development of tolerance, and, in addition, , it has a beneficial effect on sleep and sleep architecture, characterized by the enhancement of slow-wave sleep. and produces less severe cognitive and psychomotor impairment;